Molecular engineering for health
Trimerbody ™: The next generation of therapeutic antibodies
LeadArtis is a biopharmaceutical company engaged in the development of proprietary therapeutic antibodies named Trimerbodies with higher multivalence and multispecificity than the immunoglobulins, which are currently most prevalent on the market.
Our drug candidates are derived from in-house R&D and our collaborations with reference research centers and other companies. We have several proprietary programs developing in multiple therapeutic areas, including immune-oncology, which is a high-growth area for companies and investors. LeadArtis offers an opportunity to participate in the development of cutting-edge immunomodulatory therapies against cancer.
Trimerbody® is a registered trademark and is covered by international patents.
By creating new medicines, we can create hope for future patients suffering from cancers for which current therapies are inadequate.
Next Generation of Therapeutic Antibodies
We are glad to report that in a recently published EMBO Journal paper “Neutralization of…
«Tumor-targeted costimulatory trimerbodies for cancer Immunotherapy”- A brief discussion with Juan Perez Villar, CEO,...
June 7, 2021 MarketsandMarkets Conferences Doctor in Immunology from the Autonomous University of Madrid (Spain), extensive…
El director de la unidad de inmunoterapia del cáncer del Instituto de Investigación del Hospital…